日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

中国临床肿瘤学会（CSCO）：结直肠癌诊疗临床指南（2024年更新版）

期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.12639
Wang, Feng; Chen, Gong; Zhang, Zhen; Yuan, Ying; Wang, Yi; Gao, Yuan-Hong; Sheng, Weiqi; Wang, Zixian; Li, Xinxiang; Yuan, Xianglin; Cai, Sanjun; Ren, Li; Liu, Yunpeng; Xu, Jianmin; Zhang, Yanqiao; Liang, Houjie; Wang, Xicheng; Zhou, Aiping; Ying, Jianming; Li, Guichao; Cai, Muyan; Ji, Gang; Li, Taiyuan; Wang, Jingyu; Hu, Hanguang; Nan, Kejun; Wang, Liuhong; Zhang, Suzhan; Li, Jin; Xu, Rui-Hua
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Circ-malat1 promotes gastric cell growth via miR-154-5p/CCND2

Circ-malat1 通过 miR-154-5p/CCND2 促进胃细胞生长

期刊:Frontiers in Genetics
影响因子:2.8
doi:10.3389/fgene.2025.1594354
Li, Lina; Yang, Liuqing; Wang, Yuzhen; Nan, Kejun
细胞生物学
CND2
发表日期：2025
文献求助 收藏

Retraction Note: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway

撤稿声明：外泌体microRNA-32-5p通过PI3K/Akt通路诱导肝细胞癌产生多药耐药性。

期刊:Journal of Experimental & Clinical Cancer Research
影响因子:12.8
doi:10.1186/s13046-023-02761-7
Fu, Xiao; Liu, Mengjie; Qu, Shengyang; Ma, Jiequn; Zhang, Yamin; Shi, Tingting; Wen, Hongqing; Yang, Yujuan; Wang, Shuhong; Wang, Jing; Nan, Kejun; Yao, Yu; Tian, Tao
外泌体
肿瘤
肿瘤免疫
信号转导
PI3K/Akt
细胞生物学
发表日期：2023
文献求助 收藏

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

根据 EGFR 突变状态评估安罗替尼作为非小细胞肺癌三线治疗的疗效：ALTER0303 随机 3 期研究的亚组分析

期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-22-320
Zhao, Yizhuo; Wang, Qiming; Zhang, Li; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Chen, Weiqiang; Luo, Yi; Wu, Lin; Wang, Xiuwen; Nan, Kejun; Jin, Faguang; Dong, Jian; Li, Baolan; Yamaguchi, Fumihiro; Breadner, Daniel; Nagano, Tatsuya; Tanaka, Fumihiro; Husain, Hatim; Li, Kai; Han, Baohui
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2022
文献求助 收藏

Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017

1990年至2017年全球、区域和国家非霍奇金淋巴瘤负担：2017年全球疾病负担研究的估计

期刊:
影响因子:
doi:10.1080/07853890.2022.2039957
Sun, Haifeng; Xue, Li; Guo, Yahuan; Du, Jianqiang; Nan, Kejun; Li, Ming
淋巴瘤
发表日期：2022
文献求助 收藏

Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

在接受三线安罗替尼治疗的鳞状细胞肺癌（SCC）患者中，高血压的发生与无进展生存期相关：ALTER0303试验的事后分析

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.14076
Shi, Jianhua; Chen, Guimin; Wang, Haitao; Wang, Xiuxiu; Han, Baohui; Li, Kai; Wang, Qiming; Zhang, Li; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Chen, Weiqiang; Luo, Yi; Wu, Lin; Wang, Xiuwen; Nan, Kejun; Jin, Faguang; Dong, Jian; Li, Baolan; Liu, Zhian
肺癌
肿瘤
高血压
肿瘤免疫
心血管
细胞生物学
发表日期：2021
文献求助 收藏

MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC

MicroRNA-561通过靶向P-REX2a，经由PTEN/AKT信号通路影响非小细胞肺癌细胞的增殖和细胞周期转换。

期刊:Oncology Research
影响因子:4.1
doi:10.3727/096504019X15732109856009
Liao, ZiJun; Zheng, Qi; Wei, Ting; Zhang, YanBing; Ma, JieQun; Zhao, Zheng; Sun, HaiFeng; Nan, KeJun
信号转导
PTEN
AKT
肺癌
肿瘤
细胞生物学
肿瘤免疫
发表日期：2020
文献求助 收藏

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial

福沙匹坦与阿瑞匹坦在预防接受顺铂类化疗患者化疗引起的恶心呕吐方面的疗效比较：一项多中心、随机、双盲、双模拟、阳性对照的III期临床试验

期刊:Annals of Translational Medicine
影响因子:
doi:10.21037/atm.2019.12.158
Zhang, Zhonghan; Yang, Yunpeng; Lu, Ping; Li, Xiaoqin; Chang, Jianhua; Zheng, Rongsheng; Zhou, Lei; Chen, Shaoshui; Chen, Xiaopin; Ren, Biyong; Gu, Wei; Jiang, Xiaodong; Peng, Jiyong; Huang, Miaolong; Feng, Guosheng; Shen, Peng; Zhang, Qingyuan; Zhang, Baihong; Huang, Yan; He, Jingdong; Chen, Yinglan; Cao, Jingxu; Wang, Hong; Li, Wei; Wan, Huiping; Nan, Kejun; Liao, Zijun; Zhang, Cuiying; Lin, Zhong; Zhong, Diansheng; Xu, Qing; Liu, Hailong; Sun, Tao; Deng, Yanming; Zhang, Li
发表日期：2020
文献求助 收藏

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial

既往治疗策略对盐酸安罗替尼作为三线治疗晚期非小细胞肺癌（NSCLC）患者疗效的影响：ALTER0303试验的亚组分析

期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr.2019.09.21
Wang, Lili; He, Zhen; Yang, Sen; Tang, Hong; Wu, Yufeng; Li, Shaomei; Han, Baohui; Li, Kai; Zhang, Li; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Chen, Weiqiang; Luo, Yi; Wu, Lin; Wang, Xiuwen; Nan, Kejun; Jin, Faguang; Dong, Jian; Li, Baolan; Sun, Yan; Wang, Qiming
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
发表日期：2019
文献求助 收藏

Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303

晚期非小细胞肺癌患者安罗替尼相关不良事件的管理：ALTER-0303 研究经验

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.12977
Si, Xiaoyan; Zhang, Li; Wang, Hanping; Zhang, Xiaotong; Wang, Mengzhao; Han, Baohui; Li, Kai; Wang, Qiming; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; Shi, Yuankai; Chen, Weiqiang; Wang, Xiuwen; Luo, Yi; Nan, Kejun; Jin, Faguang
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏